Semi-Annual Consolidated Statement Of Cash Flows

株式会社PRISM BioLab - Filing #7335633

Concept 2023-10-01 to
2024-03-31
As at
2024-03-31
2022-10-01 to
2023-09-30
As at
2023-09-30
2021-10-01 to
2022-09-30
As at
2022-09-30
As at
2021-09-30
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-335,448,000 JPY
-525,704,000 JPY
74,157,000 JPY
Depreciation
8,737,000 JPY
1,208,000 JPY
Impairment losses
12,593,000 JPY
28,151,000 JPY
4,508,000 JPY
Foreign exchange losses (gains)
-15,963,000 JPY
-138,000 JPY
-10,486,000 JPY
Decrease (increase) in trade receivables
-3,670,000 JPY
21,721,000 JPY
-20,411,000 JPY
Other, net
40,762,000 JPY
-4,095,000 JPY
-132,000 JPY
Subtotal
341,336,000 JPY
-512,998,000 JPY
104,067,000 JPY
Income taxes paid
-1,209,000 JPY
-1,209,000 JPY
-1,212,000 JPY
Net cash provided by (used in) operating activities
340,140,000 JPY
-513,811,000 JPY
102,962,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-6,126,000 JPY
-34,589,000 JPY
-5,717,000 JPY
Net cash provided by (used in) investing activities
-24,536,000 JPY
-40,377,000 JPY
-7,874,000 JPY
Cash flows from financing activities
Redemption of bonds
JPY
-100,000,000 JPY
Proceeds from issuance of shares
1,494,750,000 JPY
JPY
210,872,000 JPY
Net cash provided by (used in) financing activities
1,494,750,000 JPY
JPY
110,872,000 JPY
Effect of exchange rate change on cash and cash equivalents
15,963,000 JPY
138,000 JPY
10,486,000 JPY
Net increase (decrease) in cash and cash equivalents
1,826,317,000 JPY
-554,050,000 JPY
216,447,000 JPY
Cash and cash equivalents
2,960,261,000 JPY
1,133,943,000 JPY
1,687,993,000 JPY
1,471,546,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.